Technical Analysis for OCGN - Ocugen, Inc.

Grade Last Price % Change Price Change
D 5.64 -2.42% -0.14
OCGN closed down 2.42 percent on Monday, April 19, 2021, on 23 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: May 6
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical OCGN trend table...

Date Alert Name Type % Chg
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion -2.42%
Gapped Down Weakness -2.42%
Lower Bollinger Band Touch Weakness -2.42%
Wide Bands Range Expansion -8.29%
20 DMA Resistance Bearish -18.26%
Older End-of-Day Signals for OCGN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 2% about 18 hours ago
Up 1% about 18 hours ago
Down 5% about 18 hours ago
Down 3% about 18 hours ago
Down 2 % about 18 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Eye Organ Systems Ophthalmology Retina Diabetic Retinopathy Blindness Eye Disease Vision Retinitis Retinopathy Eye Diseases Host Disease Retinitis Pigmentosa Graft Versus Host Disease Host Diseases Innovative Therapies Ocular Surface Diseases

Is OCGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 18.77
52 Week Low 0.17
Average Volume 52,959,231
200-Day Moving Average 2.69
50-Day Moving Average 8.58
20-Day Moving Average 6.86
10-Day Moving Average 6.50
Average True Range 0.92
ADX 15.88
+DI 26.34
-DI 27.84
Chandelier Exit (Long, 3 ATRs ) 7.59
Chandelier Exit (Short, 3 ATRs ) 8.05
Upper Bollinger Band 8.21
Lower Bollinger Band 5.51
Percent B (%b) 0.05
BandWidth 39.38
MACD Line -0.55
MACD Signal Line -0.45
MACD Histogram -0.1067
Fundamentals Value
Market Cap 913.83 Million
Num Shares 162 Million
EPS -4.83
Price-to-Earnings (P/E) Ratio -1.17
Price-to-Sales 631.47
Price-to-Book 3.82
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.60
Resistance 3 (R3) 6.59 6.26 6.44
Resistance 2 (R2) 6.26 6.02 6.27 6.39
Resistance 1 (R1) 5.95 5.86 6.11 5.96 6.33
Pivot Point 5.62 5.62 5.70 5.63 5.62
Support 1 (S1) 5.31 5.38 5.47 5.32 4.95
Support 2 (S2) 4.98 5.22 4.99 4.89
Support 3 (S3) 4.67 4.98 4.84
Support 4 (S4) 4.68